Compare HMY & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HMY | GH |
|---|---|---|
| Founded | 1950 | 2011 |
| Country | South Africa | United States |
| Employees | 34350 | N/A |
| Industry | Precious Metals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 13.3B |
| IPO Year | N/A | 2018 |
| Metric | HMY | GH |
|---|---|---|
| Price | $18.38 | $90.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 19 |
| Target Price | $16.00 | ★ $119.79 |
| AVG Volume (30 Days) | ★ 4.9M | 2.1M |
| Earning Date | 02-04-2016 | 05-07-2026 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $982,021,000.00 |
| Revenue This Year | $37.43 | $33.30 |
| Revenue Next Year | $27.44 | $28.27 |
| P/E Ratio | $15.60 | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $13.03 | $36.36 |
| 52 Week High | $26.04 | $120.74 |
| Indicator | HMY | GH |
|---|---|---|
| Relative Strength Index (RSI) | 56.17 | 54.40 |
| Support Level | $16.06 | $89.32 |
| Resistance Level | $19.13 | $101.77 |
| Average True Range (ATR) | 0.64 | 5.26 |
| MACD | 0.43 | 0.85 |
| Stochastic Oscillator | 63.22 | 72.88 |
Harmony Gold Mining Co Ltd is engaged in gold mining and related activities, including exploration, extraction, and processing. The group's primary product is gold bullion, produced at operations in South Africa and Papua New Guinea. Gold byproducts include uranium and silver. Strategic projects such as the Wafi-Golpu Project in the New Guinea Mobile Belt, the Eva Copper Project in the Mt Isa Inlier, Queensland, Australia, and the MAC Copper acquisition position the company as a gold-copper producer. The company operates across South Africa, Papua New Guinea, and Australia.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.